 

Active ingredient: Aspirin; Butalbital; Caffeine; Codeine Phosphate 

 

Form/Route: Capsules/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

 Design: Single-dose, two-way crossover in-vivo 

 Strength: 325 mg/50 mg/40 mg/30 mg 

 Subjects: Healthy males and nonpregnant females, general population 

Additional Comments: None 

_______________________________________________________________________ 

 

2. Type of study: Fed 

 Design: Single-dose, two-way crossover in-vivo 

 Strength: 325 mg/50 mg/40 mg/30 mg 

 Subjects: Healthy males and nonpregnant females, general population 

Additional Comments: None 

________________________________________________________________________ 

 

Analytes to measure (in plasma/serum/blood): Butalbital and codeine in plasma 

 

Bioequivalence based on (90% CI): Butalbital and codeine 

 

Waiver request of in-vivo testing: Not Applicable 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD 
website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the 
dissolution information for this product at this website. Please conduct comparative 
dissolution testing on 12 dosage units each of all strengths of the test and reference 
products. Specifications will be determined upon review of the application. 


